Curaleaf Q3 Revenue Hits Record $352.7 Million as Margins Contract
Curaleaf Holdings reported Q3 2026 revenue of $352.7M, up 10.9% YoY, but margins contracted. Net loss was $37.4M. Domestic revenue rose 8% to $294M, while international revenue grew 28% to $58.7M. Adjusted EBITDA increased to $77.6M. The company aims for $150M in full-year operating cash flow, with $104.9M cash and $636.9M debt at Q3 end. It also pursued Aurora Cannabis acquisition.
How this was made
The 30-second read
Why it matters
The earnings release provides fresh data on revenue growth versus profitability, influencing short‑term price action and sector sentiment.
Market read
First‑time Q3 earnings disclosure with record revenue but margin compression, creating a mixed signal for traders.
What to watch
Potential cash‑flow rebound in Q4 from timing effects and ongoing Aurora acquisition talks may mitigate short‑term concerns.
Background
Curaleaf is a leading multi‑state cannabis operator with expanding international presence.
Market effects
Cannabis sector may see broader scrutiny on margin pressures as peers report similar cost challenges.
U.S. cannabis operators could face tighter investor sentiment, while international markets remain less affected.
Limited to cannabis industry; no macro‑wide impact.
Counterpoint
Revenue growth could signal a longer‑term upside if margin issues are resolved, suggesting a buying opportunity on dip.
Key entities
- ExecutiveBoris Jordan
Chairman and CEO of Curaleaf, provided commentary on growth and cash‑flow outlook.
